Contact Us

Technologies

Pioneering the Future of Cardiac Care

Rithim is focused on the development of surgical delivery instruments and gene therapies to prevent fast heart rates originating in both the heart’s atria and/or ventricles.

These fast heart rates include both atrial fibrillation (AF) and ventricular tachycardia (VT) both of which can be debilitating and lethal.

Rithim Biologics® is developing products to prevent post operative atrial fibrillation (POAF), atrial fibrillation (AF), and ventricular tachycardia (VT).

TheraKit™ SafeBrush™

SafeBrush patent pending, adenovirus gene therapy applied during open heart surgery.

Surgical Approach: Open Chest

Application: During cardiac surgery

Target: POAF & AF prevention

TheraKit™ DAAViS™ Catheter

DAAViS Catheter US Patent 11,369,773 B2, AAV gene therapy applied during a minimally invasive procedure.

Surgical Approach: Minimally Invasive

Application: During minimally uinvasive procedures

Target: Long-term AF or VT prevention

Target: POAF
Target: AF
Target: VT

Target: POAF

Atrial Fibrillation (AF) and Post Operative Atrial Fibrillation (POAF)
  • Heart Rate Chaotic Fast
  • Affects Blood Flow
  • Increased Risk
    • Stroke
    • Heart Attack
    • Heart Failure
Key Statistics
  • ~ 480k worldwide patients impacted annually
  • POAF risk highest 2-10 days after cardiac surgery
  • Extends hospitalization by ~ 2 days
  • Cost increase $ 10 - 16k per patient
Treatment Solution

TheraKit™ with SafeBrush™ , patent pending, and adenovirus gene therapy applied during open heart surgery.

Caution: TheraKit, SafeBrush and POAF gene therapy are not approved for human use.

Target: AF

Atrial Fibrillation Facts
  • Most common type of cardiac arrhythmia
  • Leading cardiac cause of stroke
  • Found in approximately 9% of individuals over age 75
Global Impact
  • Approximately 12.1 million people in the US
  • > 30 million worldwide
Treatment Solution

TheraKit™ – DAAViS™ catheter , US Patent 11,369,773 B2, AAV gene therapy applied during a minimally invasive procedure.

With Long Term Gene Therapy to Prevent AF Applied during a minimally invasive procedure.

Caution: TheraKit, DAAViS catheter and AF gene therapy are not approved for human use.

Target: VT

Ventricular Tachycardia (VT)
  • Originates in Lower Chambers of the Heart
  • Heart Rate Fast 100 – 250 beats per minute
  • Can be irregular or regular
Symptoms & Risks
  • Dizziness
  • Fainting
  • Shortness of Breath
  • Death
Can Be Caused By Ischemic Heart Disease
  • World's Biggest Killer
  • 8.9 Million Deaths in 2019
  • 16% of the World's Total Deaths
  • Cardiac Scarring Causes VT
  • Ischemic Heart Disease Causes Cardiac Scarring
Treatment Solution

TheraKit™ – DAAViS™ catheter , US Patent 11,369,773 B2, AAV gene therapy applied during a minimally invasive procedure.

Caution: TheraKit, DAAViS catheter and VT gene therapy are not approved for human use.

Contact Us